Precigen enters into agreement to divest non-healthcare subsidiary trans ova genetics

–  precigen enters into agreement to sell wholly-owned subsidiary trans ova genetics to urus for $170 million in upfront cash and up to $10 million earn-out over two years; close expected in q3 2022 – –  transaction, upon closing, will solidify balance sheet and the company intends to pay the senior convertible notes when due in july 2023 – –  divestiture of this non-healthcare subsidiary will largely complete precigen's strategy to focus exclusively on healthcare – germantown, md. , july 5, 2022 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, trans ova genetics, l.c.
PGEN Ratings Summary
PGEN Quant Ranking